Senzime signs cooperation agreement with Philips
Press release; Uppsala, January 23, 2018. Senzime AB (publ) has signed a license and cooperation agreement with Philips to allow the TetraGraph Neuromuscular Monitoring System to communicate with Philips IntelliVue patient monitors worldwide.
Philips is one of the global leaders in the field of patient monitoring. The centralized Philip IntelliVue systems is one of the most advanced technologies in the field. Flexible access to critical physiologic patient data provides advanced clinical decision support, enhancing care and streamlining workflow.
Senzime’s TetraGraph neuromuscular monitor is a unique digital system designed to address the needs of perioperative monitoring of physiologic data in surgical patients receiving general anesthesia and muscle relaxation using neuromuscular blocking drugs (NMBAs). The TetraGraph stimulates a peripheral nerve and measures, analyzes and displays in real-time the muscle function in surgical patients who receive NMBAs as part of their general anesthetic.
Interconnected medical devices are valuable resources in the delivery of patient care. This agreement will enable TetraGraph data to be transmitted via a cable to Philips IntelliVue monitors to be displayed together with other critical patient data. The solution will be implemented in 2018.
Lena Söderström, CEO of Senzime states, "This is a milestone for Senzime as it allows critical patient information provided by the TetraGraph to be displayed on all Philips IntelliVue patient monitors worldwide. Our data will be treated no differently than any other data in the system, thus enabling the user to integrate it in their standard Patient Data Management System.”
The agreement has an initial term of three years and will automatically renew for subsequent one-year terms unless either party declines to renew it. The agreement is in line with Senzimes corporate strategy seeking alliances with the mayor providers of large central monitoring stations. Integration is conditioned upon local regulatory approvals of TetraGraph. There is no payment or other monetary support from Philips following this agreement.
For further information, please contact:
Lena Söderström, CEO of Senzime AB
Tel: +46 708-16 39 12, lena.soderstrom@senzime.com
Catrin Molund, Business Development Director
Tel: +46 708-11 69 11 catrin.molund@senzime.com
TO THE EDITORS
About Senzime
Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime. www.senzime.com
This information is insider information that Senzime AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on January 23, 2018.
Tags:
